Oncology

In preclinical research, T-cells bearing TK-8001's TCR showed better in vivo antitumor activity than T-cells incorporating human donor-derived TCRs.

The first 6 patients dosed in the ANTLER trial had a 50% CR rate at 6 months.

ITIL-306 utilizes a CoStAR molecule intended to improve cytokine release, cytolytic activity, and proliferation of TILs.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The executive director of Hemophilia Foundation Southern California discussed issues with minorities accessing care for rare diseases and strategies to mitigate them.

NKGen plans to initiate a phase 1 trial pd SNK02 in the first quarter of 2023.

The approval was based on data from ZUMA-7, a phase 3 clinical trial.

With so many therapies on the horizon, the clinical and patient communities need to be adequately prepared to support them.

The therapy is currently being evaluated in the phase 1/2 ARYA-1, ARYA-2, and ARYA-3 studies in adults and children.

The first patient has been dosed in a phase 2 study of the allogeneic CAR T-cell therapy GC007g.

The director of translational research in myeloma at the Tisch Cancer Institute discussed positive findings, including a 30-month PFS in study participants.

Review top news and interview highlights from the week ending October 14, 2022.

The chief scientific officer of cell therapy at Poseida Therapeutics discussed the company’s CAR-T and TCR technologies.

The first patient dosed with IOV-4001 has completed the safety observation period.

The chief medical officer of Triumvira Immunologics discussed the company’s future plans.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

ORR was 80% in the first cohort of phase 1b at the recommended phase 2 dose.

A retrospective study measured correlations of ICANS and NfL in patients with a history of diffuse large B-cell lymphoma.

ALLO-501A received RMAT designation from the FDA in June 2022.

Lyell will soon initiate a phase 1 trial of LYL845 with initial data expected in 2024.

Review top news and interview highlights from the week ending October 7, 2022.

The director of translational research in myeloma at the Tisch Cancer Institute discussed investigating sequential T cell redirection therapies.

Interim data from an ongoing study demonstrate continuing efficacy in B-NHL, CLL, and FL.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Oncternal will soon initiate a phase 1/2 dose-escalation study of ONCT-808.